High Tech / Life Sciences
Our firm boasts extensive experience in advising Israeli and foreign companies in the fields of pharmaceuticals, biotechnology, medical instrumentation, and digital health.
The firm represents both Israeli and international entrepreneurs, venture capital funds, private funds, technology companies, companies from academic institutions and hospitals, and medical equipment companies.
Our firm’s activities in the healthcare sector include providing ongoing legal support from the R&D stage through to the finished product. This encompasses drafting applications for government support, protecting and building an intellectual property strategy, and advising on compliance with regulatory reporting requirements. We also prepare various agreements for clients, including cooperation agreements and clinical trial agreements with research institutes, academic institutions, and hospitals.
We also counsel clients in this sector on investment agreements, capital raising, and purchase transactions, as well as vis-à-vis investors.
News and updates - High Tech / Life Sciences:
CardiacSense Signs USD 32M Deal to Sell Watches in India
Our firm serves as counsel for Cardiac Sense, a startup that developed a medical watch for remote patient vital signs monitoring and detection of fever and chronic diseases. We represent the startup in all legal matters. Recently, we assisted the company in an over USD 30 million agreement to supply medical watches for use in hospitals in India.
Representing Sartorius in the acquisition of a majority stake in Biological Industries.
Our firm represented Sartorius, a leading multinational corporation in the field of life science, research and development and biopharmaceutical industry, in a transaction to acquire a majority stake in the Israeli cell culture developer Biological Industries. Sartorius acquired the majority of Biological Industries shares by way of secondary purchase of shares from the Development Company of Kibbutz Beit Haemek and private equity fund Fortissimo Capital, in consideration for USD 50 million. In addition, as part of the transaction, Sartorius and the Development Company of Kibbutz Beit Haemek signed an option to purchase/sell additional holdings in the future.
Podcast: Ariella Dreyfuss for 50inTech on Femtech
High Tech / Life Sciences
Our firm boasts extensive experience in advising Israeli and foreign companies in the fields of pharmaceuticals, biotechnology, medical instrumentation, and digital health.
The firm represents both Israeli and international entrepreneurs, venture capital funds, private funds, technology companies, companies from academic institutions and hospitals, and medical equipment companies.
Our firm’s activities in the healthcare sector include providing ongoing legal support from the R&D stage through to the finished product. This encompasses drafting applications for government support, protecting and building an intellectual property strategy, and advising on compliance with regulatory reporting requirements. We also prepare various agreements for clients, including cooperation agreements and clinical trial agreements with research institutes, academic institutions, and hospitals.
We also counsel clients in this sector on investment agreements, capital raising, and purchase transactions, as well as vis-à-vis investors.
News and updates - High Tech:
CardiacSense Signs USD 32M Deal to Sell Watches in India
Our firm serves as counsel for Cardiac Sense, a startup that developed a medical watch for remote patient vital signs monitoring and detection of fever and chronic diseases. We represent the startup in all legal matters. Recently, we assisted the company in an over USD 30 million agreement to supply medical watches for use in hospitals in India.
Representing Sartorius in the acquisition of a majority stake in Biological Industries.
Our firm represented Sartorius, a leading multinational corporation in the field of life science, research and development and biopharmaceutical industry, in a transaction to acquire a majority stake in the Israeli cell culture developer Biological Industries. Sartorius acquired the majority of Biological Industries shares by way of secondary purchase of shares from the Development Company of Kibbutz Beit Haemek and private equity fund Fortissimo Capital, in consideration for USD 50 million. In addition, as part of the transaction, Sartorius and the Development Company of Kibbutz Beit Haemek signed an option to purchase/sell additional holdings in the future.